



Non-Confidential Presentation



March 2026



FOUNDED IN 2022

by



FOCUS

Addressing high unmet medical needs associated to infections in **acute hospital settings**, amidst the growing AMR epidemic

Adopting innovative Diagnostic & Therapeutics strategies aimed at facilitating patient stratification and optimizing treatment outcomes



PIPELINE

Differentiated pipeline of **innovative, first-in-class drugs** to tackle both the causes and consequences of serious bacterial infections and AMR, including **acute respiratory infections** (HAP/VAP), **sepsis and septic shock**



TEAM

Experienced Board & Management team with a **proven track record of building successful drug development** and bringing anti-infective products to approval

A team of 30 people
as of March 2026

Addressing Major Medical Unmet Needs in ICUs Amidst AMR

AUROBAC’s R&D strategy is designed to tackle both the causes and consequences of bacterial infections in acute hospital settings, including HAP, VAP and sepsis

ACUTE RESPIRATORY INFECTIONS

Hospital-Acquired Pneumonia (HAP)



2nd most frequent HAI following UTIs
5 to 20 cases per 1000 hospital admissions,
accounting for **25% of all ICU infections**^{1,2}



Mortality rate of up to 30% in ICUs^{1,2}

Ventilator-Associated Pneumonia (VAP)



6,5 to 40 cases per 1,000
mechanical ventilator days³



Mortality rate⁴ of 13%



Mean **additional hospital costs** of around **\$40,000**
per patients in US⁵

SEPSIS



48,9 Mio cases annually^{6,7}
Sepsis develops in about
48% of HAP cases⁶



11 Mio deaths annually,
accounting for up to **20% of all deaths** worldwide^{6,7}
Mortality varies from 15-30%
in HIC to 50% or higher in LIC^{7,8}



Average hospital cost of
sepsis > **\$32,000** per
patient in HIC⁹


Alarming AMR Pandemic



- **1 in 6 bacterial infections** globally were **resistant¹⁰** to antibiotics in 2023
- AMR is one of the **10 global public health threats facing humanity**. AMR makes **infections harder to treat** and can lead to **medical complications** and a significant increase in associated morbidity and mortality rates

Worldwide incidence and mortality rates. HAI: Hospital Acquired Infection ; UTI: Urinary Tract Infection ; ICU: Intensive Care Unit ; HIC: High-income country ; LIC: Low-income country ; Mio: Million

Sources: 1. American Thoracic Society. Am J Respir Crit Care Med, 2005 ; 2. Flanders, S.A., et al. Am J Infect Control, 2006 ; 3. Rosenthal, V.D., et al. Am J Infect Control, 2012 ; 4. Melsen, W.G., et al. Lancet Infect Dis, 2013 ; 5. Kollef, M.H., et al. Crit Care Med, 2014 ; 6. Rudd KE, et al. Lancet. 2020 ; 7. Arefian, H., et al. J Infect. 2017 ; 8. Basodan, N., et al. Cureus, 2022 ; [World Sepsis Day webpage](#) ; 9. Paoli, Carly J. et al. Critical Care Medicine, 2018 ; 10. WHO Global antibiotic resistance surveillance report 2025



Leadership Team

Experienced Management Team & Board

Management Team



Florence Séjourné

Chief Executive Officer



Martin Everett

Chief Scientific Officer



Johan Frieling

Chief Medical Officer



John O'Donnell

Chief Development Officer



Julie Cervesi

Chief Business Officer



Emeline Gardette

Head of Chemistry,
Manufacturing and Controls



Frédérique Sablier-Gallis

Head of Project
Management & Operations

Board



Manos Perros, PhD

Independent Member
Chairman



Marco Taglietti, MD

Independent Member



Detlev Mennerich, PhD

Global Head - BI Venture Fund



Karl Penz, MBA

Head of Finance Innovation Unit (R&D) - BI



François Lacoste, PhD

Former Executive Committee member and
Executive VP of R&D - bioMérieux



Antonio Felici, PhD

VP - Academic Partnerships - Evotec





Thank You!

Visit aurobac-tx.com or [LinkedIn](#) for more info!